Choksi Laboratories Limited Q1 Profit Rises 49% to ₹0.58 Crore

Choksi Laboratories Limited reported net profit of ₹0.58 crore in Q1 FY27, up 48.72% from the year-earlier period, while revenue rose 7.3% year-on-year to ₹12.08 crore. The contract testing and analytical services provider also scheduled a board meeting on November 14, 2026, to consider its September-quarter and half-year results.

What did Choksi Laboratories Limited report in Q1 FY27?

Choksi Laboratories Limited reported Q1 FY27 revenue of ₹12.08 crore and net profit of ₹0.58 crore. The reported year-on-year increase in net profit was 48.72%, while sales increased 7.3% from the corresponding quarter of the previous year. Earnings per share for the June 2026 quarter stood at ₹2.82.

On a sequential basis, the performance was lower than the March 2026 quarter. Revenue declined 6.21% from ₹12.88 crore in March 2026, operating profit fell 45.45% from ₹1.10 crore to ₹0.60 crore, and net profit decreased 43.69% from ₹1.03 crore.

The quarterly figures show that profit grew from a lower base compared with the year-earlier quarter, but softened from the immediately preceding quarter. The supplied data does not state the specific operational reasons behind the sequential movement in revenue or profit.

How did annual financial performance change in FY26?

Choksi Laboratories Limited reported FY26 revenue of ₹46.22 crore, compared with ₹41.85 crore in FY25, an increase of 10.44%. Operating profit rose 48.37% to ₹3.19 crore from ₹2.15 crore in the prior financial year.

Net profit for FY26 was ₹1.96 crore, up 28.95% from ₹1.52 crore in FY25. The increase in operating profit was higher than the growth in revenue, based on the reported figures, while net profit also rose on a year-on-year basis.

Choksi Laboratories operates in contract testing and analytical services. For a business in this segment, revenue growth and operating-profit movement are key reported indicators because they show the scale of testing and analytical operations and the profitability achieved from them. The available information does not provide a business-line or customer-level revenue split.

Why is the September 2026 board meeting important?

The board meeting scheduled for November 14, 2026, is important because Choksi Laboratories is set to consider and approve unaudited financial results for the quarter and half-year ended September 30, 2026. The meeting is scheduled for 12:30 PM and is identified as the company’s 05/2026-27 board meeting.

The agenda also allows the board to consider other matters with the chairman’s permission. The supplied information does not include the approved September-quarter numbers, management commentary, dividend decisions, or any corporate action linked to the meeting.

The September-quarter outcome will provide the next disclosed comparison after the June quarter. Investors will be able to assess revenue, profitability and earnings per share against both Q1 FY27 and the corresponding September quarter of FY26 once the unaudited results are approved and released.

What do the reported figures mean for investors?

The reported figures show a contrast between annual growth, year-on-year quarterly growth and quarter-on-quarter movement. FY26 revenue, operating profit and net profit were all higher than FY25, while Q1 FY27 profit also increased from the year-earlier quarter. However, June-quarter revenue and profit were below the March-quarter levels.

For investors, the upcoming September-quarter disclosure is relevant because it can indicate whether the sequential decline seen in Q1 was limited to that quarter or continued into the first half of FY27. This is an assessment point rather than a forecast, as the supplied material does not disclose the September-quarter financial results.

The figures also underline the need to distinguish between year-on-year and quarter-on-quarter comparisons. The year-on-year comparison measures performance against the same period a year earlier, whereas the sequential comparison measures movement from the immediately preceding quarter. Both are reported for Choksi Laboratories, and they point in different directions for Q1 FY27.

Conclusion

Choksi Laboratories Limited entered FY27 after reporting FY26 revenue of ₹46.22 crore and net profit of ₹1.96 crore, both above FY25 levels. In Q1 FY27, revenue reached ₹12.08 crore and net profit rose 48.72% year-on-year to ₹0.58 crore, although both revenue and profit were lower than in the March 2026 quarter.

The next item to watch is the board’s consideration of unaudited results for the quarter and half-year ended September 30, 2026, scheduled for November 14, 2026. Those results will provide the next reported update on Choksi Laboratories’ revenue, operating profit and net profit trends.